| Ytd | -57.92% | |
| 1y | -91.21% |
| Open | 5.15 | Prev Close | 5.15 | Low | 5.15 | High | 5.15 | Mkt Cap | 2.95M |
| Vol | 713.00 | Avg Vol | 1.11M | EPS | 98.07 | P/E | 0.05 | Forward P/E | N/A |
| Beta | 1.04 | Short Ratio | 0.22 | Inst. Own | 1.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-24 | 50-d Avg | 7.13 | 200-d Avg | 14.47 | 1yr Est | 0.00 |
Toronto, ON – TheNewswire - June 30, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”)
According to the share purchase agreement (the "SPA"), pursuant to which, NeuroThera acquire
U.S. stocks rise, Dow Jones gains 200 points. NASDAQ up 0.73%, S&P 500 up 0.56%. Health care sha
Discover why SciSparc Ltd. (NASDAQ: SPRC) stock is surging today after subsidiary NeuroThera Labs re
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with
SciSparc intends to target the global multi- billion dollar GERD device marketTEL AVIV, Israel, Jan.
SciSparc shares fall after the company agrees to acquire endoscopy-related patents as it pushes into
LHX: 13% | L3Harris Technologies shares are trading higher after the company announced plans to crea
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThe
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThe
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market